#ABVX – Q2’26 EARNINGS HIGHLIGHTS ⠀ 📊 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 🔹 Net Loss: €165.9M vs. €100.8M YoY 🔹 Operating Loss: €140.3M vs. €93.7M YoY 🔹 R&D Expenses: €107.9M vs. €77.9M YoY 🔹 G&A Expenses: €30.4M vs. €16.3M YoY 🔹 Sales & Marketing Expenses: €4.6M vs. €1.5M YoY 🔹 Operating Cash Flow: €(102.5)M vs. €(66.6)M YoY 🔹 Cash & Short-Term Investments: €402.4M Key Update: 🔹 Cash runway extended into 2029 as obefazimod moves toward an NDA filing. ⠀